{"filing":{"accession_number":"0001193125-26-332736","cik":"0001395937","ticker":"SNDX","company_name":"Syndax Pharmaceuticals Inc","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"sndx-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/sndx-20260804.htm"},"events":[{"id":23884,"run_id":21601,"accession_number":"0001193125-26-332736","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Syndax's financial results for Q2 2026 (quarter ended June 30, 2026), including total revenue of $73 million (92% YoY increase), Revuforj net revenue of $54.7 million (91% YoY increase), and Niktimvo collaboration revenue of $18.1 million (67% YoY increase). The press release and presentation are furnished as Exhibits 99.1 and 99.2 under Item 2.02, which is the standard Item for earnings disclosures. The results are material to investors as they demonstrate significant commercial traction for the company's two FDA-approved products.","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24239,"accession_number":"0001193125-26-332736","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Syndax's financial results for Q2 2026 (quarter ended June 30, 2026), including total revenue of $73 million (92% YoY increase), Revuforj net revenue of $54.7 million (91% YoY increase), and Niktimvo collaboration revenue of $18.1 million (67% YoY increase). The press release and presentation are furnished as Exhibits 99.1 and 99.2 under Item 2.02, which is the standard Item for earnings disclosures. The results are material to investors as they demonstrate significant commercial traction for the company's two FDA-approved products.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:25:10.261967+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24239,"accession_number":"0001193125-26-332736","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Syndax's financial results for Q2 2026 (quarter ended June 30, 2026), including total revenue of $73 million (92% YoY increase), Revuforj net revenue of $54.7 million (91% YoY increase), and Niktimvo collaboration revenue of $18.1 million (67% YoY increase). The press release and presentation are furnished as Exhibits 99.1 and 99.2 under Item 2.02, which is the standard Item for earnings disclosures. The results are material to investors as they demonstrate significant commercial traction for the company's two FDA-approved products.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:25:10.261967+00:00","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-08-04"}]}